Siemens Healthineers’ spin‑off and AI‑driven diagnostics boost Q4 revenue, strengthen margins, and position the firm to win value‑based contracts—see how investors can benefit.
Explore AbbVie’s latest executive share moves, award wins and workplace accolades—insight into its oncology pipeline, market‑access strategy and growth outlook.
Explore how German mid‑cap pharma and biotech firms navigate patent cliffs, market‑access strategies, and M&A to sustain growth in a cautious MDAX‑era.
Fresenius’s €524 m sale of FMC shares frees capital for hospital and pharma growth, boosting ROI while aligning with Germany’s shift to value‑based care.
Pfizer secures $1.5 B from Blackstone Life Sciences to advance Berobenatide, a long‑acting GLP‑1 obesity drug with dual‑indication potential for weight loss, knee OA, and OSA.
Fresenius SE sells 13.4 M FMC shares for €524 M, boosting cash to invest in high‑margin dialysis, digital health, and AI‑driven care, aligning with Germany’s value‑based reimbursement trend.